此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

L19IL2/L19TNF用于皮肤鳞状细胞癌患者

2026年11月12日 更新者:Philogen S.p.A.

一项关于局部晚期皮肤鳞状细胞癌患者在全身治疗中进展或不耐受后瘤内注射L19IL2/L19TNF的2期研究

Open-label, single-arm, multicenter study in patients with locally advanced, histologically confirmed Cutaneous Squamous Cell Carcinoma (LacSCC) amenable to intratumoral injection, who have progressed on or are intolerant to Immune Checkpoint Inhibitor (ICI). The primary objective of the study is to evaluate the activity of intratumoral L19IL2/L19TNF, while the secondary objective is to assess the safety and efficacy. The patients will receive multiple intratumoral administrations of combined L19IL2 and L19TNF to all injectable cutaneous and subcutaneous lesions once weekly for up to 4 weeks: for those who have a partial response or stable disease as their best response, a second 4-week course L19IL2/L19TNF of four weekly injections may be administered as per treating physician judgement. Patients will be followed for a maximum of 160 weeks after beginning of treatment.

研究概览

地位

招聘中

详细说明

Tumor Assessment (TA) visits will be performed at Week 8 (Day 50 from the beginning of treatment), Week 12 (Day 78), and then every 8 weeks for the first year of Follow-up (FU). During second and third years of FU, TA visits will be performed every 12 Weeks. In case a response (CR, PR) or stable disease is observed, a confirmatory assessment of the tumor response will be performed 4 weeks after the TA visit, when the response was first recorded.

Confirmation of response will be assessed by histopathological analysis of specimens from the skin treated area by multiple punch biopsies. Confirmation of tumor responses will be centrally reviewed by an independent committee (Independent Central Review, ICR).

Patients will be followed for overall survival (OS) after a relapse or progression, and any further treatment given will be recorded until LPLV. Phone contact or any other documented contact with the patient will be recorded every 6 months for OS assessment from treatment start until the death of the patient, withdrawal of consent or until study completion (LPLV).

L19IL2/L19TNF will be administered to eligible patients under the supervision of the investigator or identified sub-investigator(s). Patients will receive intratumoral administrations of L19IL2/L19TNF into injectable cutaneous, subcutaneous tumors and nodal or in transit metastasis once weekly for up to 4 weeks. On the day of each treatment visit, all tumors to be injected should be measured and recorded (using caliper/ruler for cutaneous lesions and/or ultrasound for subcutaneous lesions). The recommended volume to be injected into the tumor(s) is dependent on the size of the lesion(s). The maximum dose to be administered in a single treatment visit is: 13 MioIU L19IL2 + 0.4 mg L19TNF. It is recommended that each lesion should receive the maximum amount possible to inject due to tumor properties at each visit.

研究类型

介入性

注册 (估计的)

92

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Athens、希腊、16121
        • 尚未招聘
        • Andreas Syngros Hospital Of Venereal And Dermatological Diseases
        • 首席研究员:
          • Alexandros Stratigos, Prof.
      • Augsburg、德国、86179
        • 招聘中
        • Universitaetsklinikum Augsburg
        • 首席研究员:
          • Julia Welzel
      • Berlin、德国、10117
        • 招聘中
        • Charite Universitaetsmedizin Berlin KöR
        • 首席研究员:
          • Thomas Eigentler, Prof.
      • Essen、德国、45147
        • 招聘中
        • Universitaetsklinikum Essen AöR
        • 首席研究员:
          • Dirk Schadendorf, Prof.
      • Halle、德国、06120
        • 招聘中
        • Universitaetsklinikum Halle (Saale) AöR
        • 首席研究员:
          • Johannes Wohlrab, Prof.
      • Heidelberg、德国、69120
        • 招聘中
        • Universitaetsklinikum Heidelberg AöR
        • 首席研究员:
          • Jessica Hassel, Prof.
      • Kiel、德国、24105
        • 招聘中
        • Universitaetsklinikum Schleswig-Holstein AöR
        • 首席研究员:
          • Katharina Kahler, Prof.
      • Tübingen、德国、72076
        • 招聘中
        • Universitaetsklinikum Tübingen AöR
        • 首席研究员:
          • Lukas Flatz, Prof.
      • Naples、意大利、80131
        • 招聘中
        • IRCCS Istituto Nazionale Tumori Fondazione Pascale
        • 首席研究员:
          • Paolo Ascierto, Prof.
      • Roma、意大利、00168
        • 招聘中
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
        • 首席研究员:
          • Ketty Peris, Prof.
      • Rozzano、意大利、20089
        • 招聘中
        • Humanitas Mirasole S.p.A.
        • 首席研究员:
          • Paolo Bossi, Prof.
      • Siena、意大利、53100
        • 招聘中
        • Azienda Ospedaliero-Universitaria Senese
        • 首席研究员:
          • Annamaria Di Giacomo, Prof.
    • California
      • Orange、California、美国、92868-3201
        • 招聘中
        • UC Irvine Health- Chao Family Comprehensive Cancer Center
        • 首席研究员:
          • Maki MD Yamamoto
    • Georgia
      • Atlanta、Georgia、美国、30322
        • 招聘中
        • Winship Cancer Institute, Emory University
        • 首席研究员:
          • Michael C. Lowe, MD
    • Massachusetts
      • Boston、Massachusetts、美国、02215
        • 招聘中
        • Dana-Farber Cancer Institute
        • 首席研究员:
          • Emily Ruiz, MD
    • North Carolina
      • Durham、North Carolina、美国、27710
        • 招聘中
        • Duke University Medical Center
        • 首席研究员:
          • Melodi J Whitley, MD
    • Ohio
      • Columbus、Ohio、美国、43210
        • 尚未招聘
        • The Ohio State University Wexner Medical Center Clinical Laboratories
        • 首席研究员:
          • Carlo Contreras, MD
    • Texas
      • Houston、Texas、美国、77030
        • 招聘中
        • The University of Texas MD Anderson Cancer Center
        • 首席研究员:
          • Michael R Migden, MD
      • Barcelona、西班牙、08036
        • 招聘中
        • Hospital Clinic De Barcelona
        • 首席研究员:
          • Augustin Toll Abello

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patients must have histologically documented, locally advanced cSCC.
  • Patients must have at least one injectable and measurable cutaneous or subcutaneous lesion.
  • Patients must have locally advanced cSCC that has progressed on or cannot tolerate ICI treatment (adjuvant or first line) as assessed by a local multidisciplinary tumor board.
  • Patients with nodal, regional or in transit injectable cSCC lesions.
  • Patients must be willing to provide tissue from a core or excisional biopsy of a tumor lesion at screening and for confirmation of Objective Response or Stable Disease.
  • Male or female patients, who are capable of giving consent, age ≥ 18 years.
  • ECOG Performance Status/WHO Performance Status ≤ 2.
  • Hemoglobin > 10.0 g/dL.
  • Platelets > 100 x 109/L.
  • ALT and AST, GGT and Lipase ≤ 1.5 x the upper limit of normal (ULN).
  • All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v. 5.0) Grade ≤ 1 unless otherwise specified.
  • Women of childbearing potential (WOCBP) must have negative pregnancy test results at screening. WOCBP must be using, from screening to three months following the last study drug administration, highly effective contraception methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion, vasectomised partner.
  • Male patients with WOCBP partners must agree to use simultaneously two acceptable methods of contraception (i.e. spermicidal gel plus condom) from the screening to three months following the last study drug administration.
  • Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion Criteria:

  • Presence of concomitant malignancies, with the exception of any cancer curatively treated more than 3 years prior to study entry and of tumors with a negligible risk for metastasis or death, such as adequately treated basal cell carcinoma of the skin (surgically removed at least 4 weeks prior to study entry), ductal carcinoma in situ of the breast, or carcinoma in situ of the cervix, early-stage asymptomatic CLL and not under active treatment (Rai 0, Binet A) will be eligible for the study.
  • Radiation therapy on the tumor sites in the 4 weeks prior to study drug administration.
  • Current topical or systemic chemotherapy, immunotherapy.
  • Presence of visceral metastasis.
  • disease/infection requiring therapy, including positive tests for human immunodeficiency virus (HIV)-1 or HIV-2 serum antibody, hepatitis B virus (HBV), or hepatitis C virus (HCV). For HBV serology, the determination of HBsAg and anti-HBcAg Ab is required. In patients with serology documenting previous exposure to HBV, negative serum HBV-DNA is required. For HCV, HCV-RNA or HCV antibody test is required. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no current infection are eligible.
  • History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris, inadequately treated cardiac arrhythmias and heart insufficiency (any grade, New York Heart Association (NYHA) criteria).
  • Any abnormalities observed during baseline ECG investigations that are considered clinically significant by the investigator.
  • Known arterial aneurysms.
  • Chronically impaired renal function as indicated by creatinine clearance < 60 mL/min/1.73m2 or for patients older than 65 years without albuminuria or proteinuria, creatinine clearance < 45 mL/min/1.73m2.
  • INR > 3.
  • Uncontrolled hypertension.
  • Known uncontrolled coagulopathy or bleeding disorder.
  • Known hepatic cirrhosis or severe pre-existing hepatic impairment.
  • Moderate to severe respiratory failure.
  • Active autoimmune disease that has required systemic treatment in past 2 years.
  • Patients have a diagnosis of immunodeficiency or are receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug. Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions and asthma/COPD is not considered an exclusion criterion.
  • Known history of allergy to IL2, TNF, or other human proteins/peptides/antibodies.
  • Pregnancy or breast-feeding.
  • Ischemic peripheral vascular disease (Grade IIb-IV).
  • Severe diabetic retinopathy.
  • Recovery from major trauma including surgery within 4 weeks prior to enrollment.
  • Solid organ transplant recipient or patient with iatrogenic or pathologic severe immune suppression.
  • Patients with a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
  • Patients who have received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.
  • Any conditions that in the opinion of the investigator could hamper compliance with the study protocol.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment

the patients will receive multiple intratumoral administrations of a mixture of L19IL2 and L19TNF to all injectable cutaneous and subcutaneous lesions once weekly for up to 4 weeks.

intratumoral administrations

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Overall Response Rate (BORR)
大体时间:From enrollment up to a maximum of 160 weeks after the start of treatment

Best Overall Response Rate (BORR) as defined by the RECIST 1.1. criteria according to an Independent Central Review (ICR).

From enrollment up to a maximum of 160 weeks after the start of treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年10月29日

初级完成 (估计的)

2031年2月1日

研究完成 (估计的)

2031年2月1日

研究注册日期

首次提交

2025年11月7日

首先提交符合 QC 标准的

2025年11月11日

首次发布 (实际的)

2025年11月14日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • PH-L19IL2TNFSCC-06/24
  • 2025-523231-19-00 (克蒂斯)
  • 2025 (美国 NIH 拨款/合同)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅